We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RGNX market cap is 361.18M. The company's latest EPS is USD -5.3183 and P/E is -1.37.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 28.91M | 22.21M | 15.66M | 22.27M | 24.2M |
| Operating Income | -64.96M | -63.9M | -63.86M | -56.04M | -62.07M |
| Net Income | -61.87M | -62.89M | -63.33M | -52.99M | -59.6M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 35.24M | 154.57M | 470.35M | 119.4M | 90.24M |
| Operating Income | -149M | -111.26M | 157.74M | -262.88M | -268.13M |
| Net Income | -94.73M | -111.25M | 127.84M | -280.32M | -263.49M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 633.79M | 573.97M | 629.22M | 569.38M | 519.11M |
| Total Liabilities | 270.69M | 262.23M | 238.55M | 221.11M | 217.7M |
| Total Equity | 363.1M | 311.74M | 390.67M | 348.27M | 301.42M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 497.91M | 708.16M | 1.11B | 833.27M | 573.97M |
| Total Liabilities | 47.71M | 330.41M | 349.61M | 317.07M | 262.23M |
| Total Equity | 450.2M | 377.75M | 764.3M | 516.2M | 311.74M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -177.65M | -218.41M | -55.46M | -100.95M | -141.5M |
| Investing | 156.97M | 190.94M | 13.18M | 12.92M | 63.17M |
| Financing | -23M | -34.97M | 120.73M | 111.28M | 100.42M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -107.71M | -54.06M | 218.88M | -207.49M | -218.41M |
| Investing | 93.56M | 122.76M | -406.64M | -11.93M | 190.94M |
| Financing | 8.38M | 200.21M | 195.25M | -28.84M | -34.97M |
| Market Cap | 361.18M |
| Price to Earnings Ratio | -1.37 |
| Price to Sales Ratio | 4.01 |
| Price to Cash Ratio | 10.49 |
| Price to Book Ratio | 1.16 |
| Dividend Yield | - |
| Shares Outstanding | 49.55M |
| Average Volume (1 week) | 1.03M |
| Average Volume (1 Month) | 1.86M |
| 52 Week Change | -58.95% |
| 52 Week High | 28.80 |
| 52 Week Low | 7.15 |
| Spread (Intraday) | 0.01 (0.14%) |
| Company Name | REGENXBIO Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.regenxbio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
